CABAZITAXEL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CABAZITAXEL (CABAZITAXEL).
Microtubule inhibitor. Binds to tubulin and promotes microtubule assembly while inhibiting disassembly, leading to mitotic arrest and cell death. Also inhibits tubulin deacetylation and has anti-angiogenic properties.
| Metabolism | Hepatic, primarily via CYP3A4/3A5; also CYP2C8. Metabolites excreted in bile and feces. |
| Excretion | Primarily hepatobiliary (76% in feces as metabolites), renal (2-3% unchanged; 20% total in urine as metabolites). |
| Half-life | Terminal half-life approximately 95 h (range 77–120 h) in patients with normal hepatic function; prolonged in hepatic impairment. |
| Protein binding | Approximately 89–92% bound to human plasma proteins (albumin and lipoproteins). |
| Volume of Distribution | Steady-state Vd ≈ 4.1 L/kg (range 3.2–5.6 L/kg), indicating extensive tissue distribution. |
| Bioavailability | Not bioavailable orally; administered intravenously. |
| Onset of Action | Intravenous: Clinical effect (e.g., tumor response) observed after 2–4 cycles (6–12 weeks); not immediate. |
| Duration of Action | Duration is cycle-dependent; typical dosing every 3 weeks; myelosuppression and other effects may persist for weeks. |
25 mg/m2 intravenously every 3 weeks in combination with oral prednisone 10 mg daily.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment recommended for mild to moderate renal impairment (CrCl >=30 mL/min). Insufficient data for CrCl <30 mL/min. |
| Liver impairment | Mild hepatic impairment (Child-Pugh A): 20 mg/m2 every 3 weeks. Moderate impairment (Child-Pugh B): 15 mg/m2 every 3 weeks. Severe impairment (Child-Pugh C): contraindicated. |
| Pediatric use | Safety and efficacy not established for pediatric patients. |
| Geriatric use | No specific dose adjustments recommended for elderly patients; monitor for increased toxicity, particularly myelosuppression and fatigue. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for CABAZITAXEL (CABAZITAXEL).
| Breastfeeding | It is unknown whether cabazitaxel or its metabolites are excreted in human milk. Due to the potential for serious adverse reactions in nursing infants, including myelosuppression, gastrointestinal toxicity, and neurotoxicity, breastfeeding is contraindicated during cabazitaxel therapy and for at least 2 weeks after the last dose. No M/P ratio data are available. |
| Teratogenic Risk | Cabazitaxel is a taxane derivative and is classified as FDA Pregnancy Category D. Based on its mechanism of action (microtubule inhibition) and animal studies showing embryotoxicity and fetotoxicity, cabazitaxel is expected to cause fetal harm when administered to a pregnant woman. In animal reproduction studies, cabazitaxel caused embryo-fetal lethality and fetal malformations at doses below the recommended human dose. There are no adequate and well-controlled studies in pregnant women. Use during pregnancy is contraindicated. First trimester exposure carries the highest risk of major congenital malformations. Second and third trimester exposure may cause fetal growth restriction, oligohydramnios, and neonatal myelosuppression. Effective contraception should be used during treatment and for at least 3 months after the last dose in females and 4 months in males. |
■ FDA Black Box Warning
Neutropenia: Severe neutropenia, including febrile neutropenia and fatal neutropenic sepsis, can occur. Monitor blood counts frequently. Do not administer if absolute neutrophil count < 1,500 cells/mm³.
| Serious Effects |
["Severe hypersensitivity to cabazitaxel or polysorbate 80","Severe hepatic impairment (Child-Pugh C)","Absolute neutrophil count < 1,500 cells/mm³","Pregnancy (FDA category D)"]
| Precautions | ["Neutropenia and febrile neutropenia: Monitor CBCs; hold or reduce dose for severe neutropenia.","Hypersensitivity reactions: Severe reactions including hypotension, bronchospasm, and rash can occur; premedicate with antihistamines and corticosteroids.","Gastrointestinal toxicity: Nausea, vomiting, diarrhea; severe diarrhea may require dose reduction.","Renal failure: Cases of renal failure reported, especially with high doses; monitor renal function.","Peripheral neuropathy: Monitor for sensory and motor neuropathy; may require dose adjustment.","Hepatic impairment: Reduce dose in mild to moderate impairment; contraindicated in severe impairment.","Cardiac toxicity: QT prolongation, arrhythmias; monitor in patients with cardiac disease.","Interstitial lung disease: Rare but serious; discontinue if suspected."] |
Loading safety data…
| Fetal Monitoring | For pregnant patients exposed to cabazitaxel (if inadvertent): serial fetal ultrasound monitoring for growth, amniotic fluid volume, and fetal anatomy. Complete blood counts (CBC) with differential for maternal and potential neonatal neutropenia. Assess for signs of preterm labor. Postnatal follow-up: evaluate newborn for myelosuppression (CBC), liver function tests, and developmental milestones. If chemotherapy is continued during pregnancy, monitor maternal renal and hepatic function, and adjust supportive care accordingly. |
| Fertility Effects | Cabazitaxel has been associated with gonadotoxicity. In males, it may cause azoospermia or oligospermia due to testicular damage; sperm cryopreservation is recommended before treatment. In females, cabazitaxel may cause ovarian failure, premature menopause, and reduced fertility; oocyte or embryo cryopreservation should be considered. The effects may be irreversible. |
| Food/Dietary |
| Avoid grapefruit and grapefruit juice as CYP3A4 interaction may alter cabazitaxel metabolism. Maintain adequate hydration. No other specific dietary restrictions. |
| Clinical Pearls | Cabazitaxel is a taxane antineoplastic agent used as second-line therapy for metastatic castration-resistant prostate cancer (mCRPC) after docetaxel. It requires premedication with antihistamines, corticosteroids, and antiemetics to reduce hypersensitivity and emesis. Monitor for severe neutropenia and febrile neutropenia; G-CSF prophylaxis is recommended. Caution in hepatic impairment (bilirubin >1x ULN or transaminases >1.5x ULN contraindicates use). Administer via IV infusion over 1 hour every 3 weeks. Do not use in patients with neutrophil counts <1,500 cells/mm³. |
| Patient Advice | This drug may lower your white blood cell count, increasing infection risk; report fever or chills immediately. · You may experience hair loss, diarrhea, nausea, vomiting, or fatigue. · Take anti-nausea medications as prescribed and drink plenty of fluids. · Avoid grapefruit and grapefruit juice during treatment as they may interact. · Use effective contraception during and for 3 months after treatment. |